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Background. The aim of this study was to investigate whether different haemofilter surface areas affect clotting and platelet
consumption in critically ill patients undergoing continuous venovenous haemodiafiltration (CVVHDF).Methods. CVVHDF was
performed in postdilution technique using a capillary haemofilter with two different membrane sizes, Ultraflux AV 1000S (𝑛 = 17,
surface 1.8m2, volume 130mL), and the smaller AV 600S (𝑛 = 16, surface 1.4m2, volume 100mL), respectively. Anticoagulation
was performed with heparin. Results. No significant differences were found when the two filters were compared. CVVHDF was
performed for 33 (7–128) hours with the filter AV 1000S and 39 (7–97) hours with AV 600S (𝑃 = 0.68). Two (1–4) filters were
utilised in both groups over this observation period (𝑃 = 0.94). Platelets dropped by 52,000 (0–212,000) in AV 1000S group and
by 89,500 (0–258,000) in AV 600S group (𝑃 = 0.64). Haemoglobin decreased by 1.2 (0–2.8) g/dL in AV 1000S group and by 1.65
(0–3.9) g/dL in AV 600S group (𝑃 = 0.51), leading to the transfusion of 1 (0–4) unit of blood in 19 patients (10 patients with AV
1000S and 9 with AV 600S). Filter observation was abandoned due to death (12.1%), need for systemic anticoagulation (12.1%),
repeated clotting (36.4%), and recovery of renal function (39.4%). Conclusion. Our study showed that a larger filter surface area did
neither reduce the severity of thrombocytopenia and anaemia, nor decrease the frequency of clotting events.
1. Introduction
Acute renal failure (ARF) has a high incidence among criti-
cally ill patients, occurring predominantly as a consequence
of shock and systemic inflammation, and leads to a prolonged
hospital length of stay and considerable costs [1–7]. ARF is
related to significantmorbidity and is an independent predic-
tor of mortality [8]. Renal replacement therapy (RRT) is the
standard of care for this condition and is generally performed
as continuous venovenous haemodiafiltration (CVVHDF) in
the intensive care unit setting [9]. The correlation between
filter characteristics, filter performance, and CVVHDF safety
in critically ill patients has rarely been subject of research,
despite the long experience of continuous renal replacement
therapy (CRRT) in clinical practice [9–14]. CVVHDF related
complications, for example, hypotension, electrolytes dis-
turbances, platelet consumption, and hypercoagulable state,
potentially lead to an unfavourable outcome among critically
ill patients with ARF [9, 15–17]. CVVHDF is also associated
with significant risk of bleeding due to the required extracor-
poral circuit anticoagulation, secondary platelet dysfunction,
and thrombocytopenia [9, 15]. Finally, recurrent filter clotting
leads to dialysis discontinuation and to frequent filter change,
resulting in reduced treatment efficacy and high costs.
In consideration of these aspects, we aimed to review
our use of two different haemodiafiltration membrane sizes
(1.8m2 versus 1.4m2) and compare the findings with regard
to platelet count, haemoglobin level, and filter longevity.
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2. Methods
2.1. Study Population. This retrospective study was per-
formed in the 12-bed medical intensive care unit (ICU) of the
University Hospital Zurich, Switzerland, and was approved
by the local ethic committee. All consecutive adult patients,
who required CVVHDF between November 2007 and June
2009, were screened for the study. Patients with coagulation
abnormalities or need for systemic anticoagulation were
excluded. Patients were included into the analysis only once,
even when they were readmitted during the observation
period. Routine clinical information and laboratory param-
eters, including parameters for haemolysis and coagulation,
were collected from the charts. The observation began with
the start of CVVHDF and ended when (a) the patient died,
(b) the patient did not require CVVHDF anymore, or (c)
the standard anticoagulation procedure was abandoned, for
example, change to predilution technique or switch to a
therapeutic anticoagulation regimen or to anticoagulation
with citrate.
Criteria for starting CVVHDF in critically ill patients
were preexisting chronic renal failure (on intermittent dial-
ysis), acute renal failure with oliguria (<500mL/d) and signs
of fluid overload according to the RIFLE and AKIN classi-
fication, hyperkalaemia (K+ > 6.5mmol/L), metabolic aci-
dosis (pH < 7.20), uremic symptoms, and poisoning with
dialysable toxins [1, 6, 18]. Patients with higher bleeding risk
or contraindications for heparin anticoagulation, for exam-
ple, thrombocytopenia, congenital or acquired coagulation
disorders, and history of severe bleeding or heparin induced
thrombocytopenia (HIT), were primarily assigned to citrate
anticoagulation and excluded from our observation.
2.2. Instruments and CVVHDF Procedure. CVVHDF was
performed with a multifiltrate machine (Fresenius, Hom-
burg, Germany) and two different capillary haemofilters,
Ultraflux AV 1000S (𝑛 = 17) and Ultraflux AV 600S (𝑛 = 16),
were utilised according to their availability. Both filters con-
tained a polysulfone membrane able to eliminate molecules
with a weight of up to 30,000 Dalton, AV 1000S having a
larger filtrating surface and bigger blood filling volume com-
pared to the smaller AV 600S filter (1.8m2 versus 1.4m2;
130mL versus 100mL). According to the manufacturer, wall
thickness and inner diameter of the capillaries were the same
in both filters. Our standard protocol required an effluent
flow rate of 35mL/kg/h and, in agreement with the accepted
practice at the time, the flow rate was increased to 50mL/kg/h
during the first 24 hours in patients with severe sepsis and
septic shock [15]. Ultrafiltrate and dialysate (Hemosol B0,
Gambro Hospal, Basel, Switzerland) fluids were replaced in
a 1 : 1 ratio, and the substitution fluid was given postfilter.
The filtration fraction was adjusted to be ≤20% of the blood
flow. Anticoagulation was performed with standard unfrac-
tionated heparin, given before the filter, the initial dose being
8U/kg/h. A first analysis of the postfilter activated partial
thromboplastin time (aPTT) was performed 2 hours after
the start of CVVHDF. The anticoagulation targets were a
postfilter and systemic aPTT between 40–50 s and <45 s,
respectively. Heparin doses were adjusted accordingly, and
aPTT measurement was repeated after 6 hours.
2.3. Statistical Analysis. Results are given as median (range)
or percentages. Comparisons between the two filter groups
were made with theMann-Whitney𝑈 test and the chi-square
test as appropriate. All testing was two-tailed and a 𝑃 value <
0.05 was considered significant. All statistical analyses were
performed with the use of SPSS 17.0 for Mac OS X.
3. Results
3.1. Patient Characteristics. 53 patients were screened and 33
were included in the analysis. Two groups of patients were
compared according to the type of filter and there were no
significant differences among their baseline characteristics
(Table 1).
Main diagnoses on ICU admission were acute heart fail-
ure (30.3%), sepsis (27.3%), and acute respiratory failure
(12.1%). The remaining 30.3% of patients were admit-
ted due to renal (3.0%), gastrointestinal (9.1%), neuro-
logic (9.1%), and endocrine disease (3.0%) and for post-
operative management after elective surgery (6.1%). Half
of included patients had a moderate to severely impaired
glomerular filtration rate (GFR < 60mL/min) already before
their admission to the ICU (Table 1). All but one had doc-
umented ARF or acute-on-chronic deterioration of renal
function at CVVHDF start. Sepsis, haemodynamic insta-
bility, and toxic renal damage (contrast medium, nonster-
oidal anti-inflammatory drug, rhabdomyolysis) were among
the precipitant causes in 16 (48.5%), 8 (24.2%), and 5
(15.2%) patients. One patient (3.0%) developed ARF due
to progressive minimal change glomerulonephritis and 2
patients (6.1%) as a complication of diabetic and hepatic
coma, respectively. One patient (3.0%) only did not show
any evidence of renal impairment and required CVVHDF for
severe hyperammonemia and related encephalopathy.
CVVHDF was started, while 69.7% of the patients were
requiring haemodynamic support with catecholamines and
72.7% were on mechanical ventilation. SAPS II and SOFA
scores were 63 (30–98) and 12 (8–16), respectively. ICU and
hospital length of staywere 8 (1–168) days and 22 (2–171) days.
Overall, ICU mortality reached 33.3% and hospital mortality
42.4% (Table 1).
3.2. Filter Comparison and Safety. Baseline laboratory pa-
rameters at CVVHDF start were similar between patients
treated with AV 1000S andAV 600S filters, with the exception
of the potassium level (𝑃 = 0.03, Table 1). The results of the
filter performance analysis are shown in Table 2.
There was no difference in creatinine and blood urea
nitrogen (BUN) clearance, or in heparin dose needed for
extracorporal circuit patency. During the first six hours
of CVVHDF, patients received 450 (0–1050)U/h heparin,
representing a dose of 7 (0–9)U/kg/h. Postfilter aPTT 6
hours after starting CVVHDFwas 51 (27–115) s. After 6 hours,
only 15% of the postfilter aPTT measurements were within
our predefined target range of 40–50 s, whereas 30% were
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Table 1: Baseline patient characteristics and laboratory parameters at CVVHDF start.
All patients
(𝑛 = 33)
Filter AV 1000S
(𝑛 = 17)
Filter AV 600S
(𝑛 = 16) 𝑃 value
Age—yr 68 (35–87) 68 (35–87) 67 (35–86) 0.82
Male sex—number (%) 21 (64%) 11 (65%) 10 (63%) 0.90
BMI—kg/m2 24.6 (14.6–41.5) 26.7 (18.3–41.5) 20.8 (14.6–37.7) 0.07
SOFA score 12 (8–16) 12 (8–15) 12 (8–16) 0.58
SAPS II score 63 (30–98) 63 (30–98) 60 (37–94) 0.87
Noradrenaline—number (%) 23 (69.7%) 13 (76.5%) 10 (62.5%) 0.38
Mechanical ventilation—number (%) 24 (72.7%) 13 (76.5%) 11 (68.7%) 0.56
Admission diagnoses—number (%) 0.33
Cardiovascular 10 (30.3%) 7 (41.2%) 3 (18.8%)
Sepsis 9 (27.3%) 5 (29.4%) 4 (25.0%)
Respiratory 4 (12.1%) 1 (5.9%) 3 (18.8%)
Others 10 (30.3%) 4 (23.5%) 6 (37.4%)
Length of ICU stay—days 8 (1–168) 8 (3–44) 8 (1–168) 0.79
Length of hospital stay—days 22 (2–171) 19.5 (3–61) 25.5 (2–171) 0.53
ICU mortality—𝑛. (%) 11 (33.3%) 7 (41.2%) 4 (25.0%) 0.33
Hospital mortality—𝑛 (%) 14 (42.4%) 8 (47.1%) 6 (37.5%) 0.58
Creatinine—umol/L 299 (26–909) 320 (210–649) 262 (26–909) 0.28
BUN—mmol/L 21.9 (2.8–40.1) 20.1 (2.8–40.1) 22.1 (3.8–37.3) 0.68
Potassium—mmol/L 4.8 (3.2–6.7) 5.3 (3.9–6.7) 4.6 (3.2–6.4) 0.03
pH 7.30 (6.86–7.49) 7.30 (7.04–7.44) 7.28 (6.86–7.49) 0.64
Lactate—mmol/L 1.2 (0.5–14.7) 1.5 (0.5–4.3) 1.1 (0.5–14.7) 0.46
Bicarbonate—mmol/L 17.9 (6.1–29.8) 19.5 (11.1–29.8) 16.3 (6.1–29.3) 0.18
Platelet count—1/uL 189,000 (47,000–522,000) 189,000 (95,000–522,000) 191,500 (47,000–422,000) 0.59
Haemoglobin—g/dL 8.9 (6.7–15.3) 9.1 (7.7–10.2) 8.9 (6.7–15.3) 0.82
Renal function before admission to ICU‡ 0.42
GFR > 60mL/min 15 (45.5%) 9 (52.9%) 6 (37.5%)
GFR < 60mL/min 17 (51.5%) 8 (47.1%) 9 (56.3%)
Results are given as median (range) or percentages; BMI: body mass index; SOFA: sequential organ failure assessment; BUN: blood urea nitrogen; GFR:
glomerular filtration rate.
‡Total number of patients = 32; filter AV 1000S = 17; filter AV 600S = 15.
Table 2: Filter longevity and CVVHDF setting.
All patients
(𝑛 = 33)
Filter AV 1000S
(𝑛 = 17)
Filter AV 600S
(𝑛 = 16) 𝑃 value
Numbers of filters—number 2 (1–4) 2 (1–4) 2 (1–4) 0.94
CVVHDF observation period—hours 35 (7–128) 33 (7–128) 39 (7–97) 0.68
Filter longevity—hours 17 (4–67) 15 (4–67) 21 (4–42) 0.63
Haemodiafiltration rate—mL/kg/h 35 (35–80) 35 (35–50) 35 (35–80) 0.75
Ultrafiltration rate—% 17 (9–24) 17 (12–24) 17 (9–20) 0.90
Blood flow—mL/min 150 (100–240) 150 (100–230) 150 (100–240) 0.50
Heparin dose first 6 hours—U/h 450 (0–1050)¶ 500 (0–1050) 400 (250–900) 0.17
Heparin dose first 6 hours/body weight—U/h/kg 7.1 (0–9.1)¶ 7.3 (0–9.1) 6.7 (3.4–8.6) 0.17
Absolute creatinine drop—umol/L 171 (8–830)‡ 221 (97–562) 157 (8–830) 0.48
Relative creatinine drop—% 64 (7–91) 67 (29–87) 69 (7–91) 0.98
Absolute BUN drop—mmol/L 9.5 (0–30.8) 7.3 (0–30.5) 11 (0–30–8) 0.64
Relative urea drop—% 53 (0–85) 53 (0–77) 54 (0–85) 0.54
Results are given as median (range) or percentages.
¶Total number of patients = 28; filter AV 1000S = 15; filter AV 600S = 13.
‡Total number of patients = 27; filter AV 1000S = 13; filter AV 600 = 14.
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Figure 1: Postfilter aPTT values two and six hours after CVVHDF initiation.
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Figure 2: Changes in platelet counts with CVVHDF.
below and 55% above this range (Figure 1). Postfilter aPTT
measurements were missing in 5 patients after 2 hours and in
13 after 6 hours.
Creatinine and BUN decreased significantly (𝑃 < 0.001)
with CVVHDF, but there was no difference in efficacy
between the two filters. Bicarbonate increased by 4.7mmol/L
(23% of the baseline value) to 24 (5.3–29.7)mmol/L at the end
of the observation period.
During CVVHDF, thrombocytopenia was a common
finding and platelet count dropped by 52,000 (0–212,000)
and 89,500 (0–258,000) using AV 1000S and AV 600S filter,
respectively (𝑃 = 0.64, Figure 2).
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Figure 3: Changes in haemoglobin concentrations with CVVHDF.
Haemoglobin decreased by 1.2 (0–2.8) g/dL in AV 1000S
group and by 1.65 (0–3.9) g/dL in AV 600S group (𝑃 = 0.51,
Figure 3), overall to the transfusion of 1 (0–4) unit of red
blood cells in 19 patients (57.6%). There were no significant
differences between the two filter groups, with 10 patients
in AV 1000S and 9 patients in AV 600S group requiring the
transfusion of 1 unit of blood (ranges 1–4 and 1–3, respectively,
𝑃 = 0.81). No platelet transfusions were needed and
no patient developed a heparin induced thrombocytopenia
(HIT).
The overall CVVHDF observation period was 33 (7–128)
hours with AV 1000S and 39 (7–97) hours with AV 600S
filter (𝑃 = 0.68), and 2 (1–4) filters were utilised in both
groups (𝑃 = 0.94). Overall filter longevity was 15 (4–67)
hours with AV 1000S and 21 (4–42) hours with AV 600S
filters (𝑃 = 0.63). Observation was abandoned due to death
(12.1%), need for systemic anticoagulation (12.1%), repeated
clotting (36.4%), and recovery of renal function (39.4%).
Among the patients requiring continuation of CVVHDF,
33.3% were changed to predilution technique and 19.5%
to intermittent renal replacement therapy and 27.7% were
started on therapeutic anticoagulation with heparin and
19.5% on citrate anticoagulation.
4. Discussion
Our retrospective study did not demonstrate any signifi-
cant difference related to the filter size but confirmed that
CVVHDF is a very effective therapy in critically ill patients
with ARF, regardless of whether an AV 1000S or an AV
600S filter is employed. Using a haemodiafiltration dose
of 35mL/kg/h, significant decreases in creatinine and BUN
levels were documented during CVVHDF lasting 35 hours.
However, repeated clotting was a common problem and
almost half of the included patients required continuation
of CVVHDF in predilution technique or with other antico-
agulation modalities. Significant drops in platelet count and
haemoglobin level were a common finding during treatment
with CVVHDF. As expected, and in line with the published
literature, overallmortality was high and 33.3%of all included
patients died during ICU admission and 42.4% during the
whole hospital admission, respectively [7, 16, 19–22].
Hypothetically, the use of a filter with a larger mem-
brane surface may turn in being beneficial due to enhanced
interleukin-6 removal and reduced resistance, facilitating
blood flow through the filtrating membrane and leading to
reduced extraction of platelets from the circuit. However,
our study did not show any significant differences in filter
longevity, bleeding complications, or need for blood transfu-
sions [23–26]. Furthermore, there was visible clot formation
in almost all haemodiafiltration circuit components, includ-
ing the venous bubble-trap chamber and the arterial and the
venous lines, suggesting that the overall filtrating system sur-
face, not the filter only, can induce repetitive clotting [26].We
can therefore conclude that the size of the effective filtrating
surface area and the blood filling volume are not the only
determinants of repetitive clotting and filter related complica-
tions. Despite its efficacy, postdilution CVVHDF can lead to
significant haemoconcentration, potentially causing higher
clotting frequency if compared with continuous venovenous
haemodialysis (CVVHD) in predilution technique. Limited
data suggest higher filter longevity in CVVHD compared to
the median filter longevity documented in our study [27].
However, there is a lack of literature comparing the two
different techniques with regard to frequency of clotting and
filter related complications in ICU patient with ARF.
The definition of an optimal anticoagulation strategy
providing longer circuit patency by minimizing potential
harms for the patient plays a crucial role in the setting of
CVVHDF. In our study, anticoagulation was performed with
unfractionated heparin using a dosing schema similar to the
algorithm recommended by Ostermann et al. [28]. Unfrac-
tionated heparin has low costs and can be easily monitored
in critically ill patients and its effect can be antagonized
with protamine. A review of the literature suggests that low
dose anticoagulation with unfractionated heparin targeting
systemic aPTT values <45 s has low risk for additional bleed-
ing in patients undergoing CRRT, but laboratory and circuit
monitoring should be performed frequently in light of the
several individual factors that influence the effectiveness and
safety of heparin anticoagulation [29, 30]. Point-of-caremon-
itoring of systemic and postfilter aPTT can be used to rapidly
adjust heparin dosing. However, according to our experience,
achieving target aPTT in critically ill patients is generally
difficult, presumably as consequence of their inflammatory
response and hypercoagulable state. Furthermore, aPTT is
reported to be poor predictor for bleeding complications [31].
In our study, major bleeding complications were not doc-
umented, but high-risk patients were primarily treated with
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other anticoagulation regimes, for example, citrate anticoag-
ulation, and excluded from the observation. Regional citrate
anticoagulation has become a valuable alternative to heparin,
especially for patients with higher bleeding risk, and might
be associated with longer filter survival and improved patient
and renal outcomes [32–35]. However, regional citrate antico-
agulation is considerably more expensive than heparin and
requires intensive monitoring of citrate accumulation and
acid-base imbalances.
Hence, the need of an individualised approach in relation
to the choice of anticoagulation regimen and its intensity
has to be emphasised, considering the high morbidity of the
critically ill patients undergoing CVVHDF.
Among the numerous CVVHDF related complications
reported in the literature [9, 15–17, 36], we predomi-
nantly documented a significant drop in platelet count and
haemoglobin level, the last leading to blood transfusion with
associated risk of adverse transfusion related events [37, 38].
Our findings concerning the amount or blood transfusions
required during CVVHDF reflected those of previous studies
[34]. In addition to bleeding due to spillover of regional
extracorporeal circuit, heparinisation or disease associated
coagulopathy, filter induced haemolysis, and blood loss due to
repeated sudden clotting of extracorporeal circuit may have
contributed to the haemoglobin drop seen in our patients. An
aPTT > 45 s was documented in a large proportion of our
patients before and after CRRT initiation. Under these condi-
tions, it is likely that occult gastrointestinal bleeding may be
the source of blood loss. Since none of the included patients
manifested significant haemolysis, the repeated clotting of the
extracorporeal circuit may have caused the blood loss.
We also observed a clinically relevant drop in platelet
count, most likely due to platelet activation and consumption
in the extracorporeal circuit [25, 39].Themagnitude of plate-
let loss observed in our study is close to that described in
patients with cardiogenic shock and acute renal failure in
need of CRRT [39]. Although a median drop of 55,000/𝜇L is
clinically relevant, none of our study patients needed platelet
transfusion; this is mainly because baseline platelet counts
were normal. Since thrombocytopenia is frequent [25] in
ICU patients, CRRT induced platelet loss may contribute to
an increased risk of bleeding and need for platelet trans-
fusion, potentially leading to a further increase in overall
costs. A patient individualized strategy to prevent repeated
extracorporeal circuit clotting and to reduce platelet loss is
thus warranted [39].
This study has several limitations, first of all the retrospec-
tive design. For this reason, both the ICU health-care person-
nel and the research staffwere not blinded for haemodiafiltra-
tion settings, anticoagulation adjustments, or data collection.
Additionally, the limited number of included patients could
have led to an underestimation of the differences between
the two filter groups and to inadequate understanding of the
clotting mechanisms. In respect of anticoagulation and its
monitoring, we could not appropriately compare the course
after six hours because of unavailable or irregularly collected
laboratory results. Finally, we defined no control group for
comparison of filter performance, for example, different
filter manufacturer, citrate anticoagulation, or intermittent
haemodialysis.
5. Conclusion
In summary, this study confirms that CVVHDFwith heparin
anticoagulation is very effective but complicated by repeated
clotting and relevant consumption in platelets and red blood
cells. In this setting, the type of filter did not result in any
significant difference. However, the retrospective character
of the study, the small number of included patients, and
observational bias could have led to underestimation of the
differences between the filters. Patients with ARF undergoing
CVVHDF remain at high risk for unfavourable outcome.
Hence, better understanding of underlying mechanisms of
clot formation during CVVDHF is needed to improve
CVVHDF safety and reduce filter related complications.
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